2015 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO SYMPOSIUM) ON IMMUNO-ONCOLOGY
- Medical_Professionals
- Medical_students
- Nurses
Major themes
Checkpoint inhibition
Cancer neo-antigens
Immunomodulatory antibodies
PD-1/PD-L1 axis blockade, results to date
Immuno-oncology meets molecular oncology
Adoptive T cell therapy
Immuno-Oncology clinical studies across tumour types (breast, lung, brain, gastrointestinal, genitourinary, gynaecology, melanoma, lymphoma)
ESMO-MORA: The Symposium programme will be submitted for ESMO-MORA category 1 points accreditation. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possesses the necessary skills and standards for the practice of medical oncology. See here for further details.
EUR
2015-09-30
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
MCH Beaulieu Lausanne SA
1000 Lausanne 22
www.congres-lausanne.ch
Submission Info
The Symposium Scientific Committee is calling for abstract submission in the following sub-specialties:
Checkpoint inhibition
Cancer neo-antigens
Immunomodulatory antibodies
PD-1/PD-L1 axis blockade
Immuno-oncology meets molecular oncology
Adoptive T cell therapy
Immuno-oncology clinical studies across tumour types (breast, lung, brain, gastrointestinal, genitourinary, gynaecology, melanoma, lymphoma)
Trials in progress
Trial in Progress abstracts in all phases of clinical research (phases I to III) may be submitted.
It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections:
Background
Trial design
Notes:
Recruitment must have already begun or have been completed by the abstract submission deadline of 8 September 2015.
Abstracts including results or preliminary data will be rejected.
Trial in Progress abstracts may not be considered for Proffered Paper (oral) presentation.
Presentation and publication of accepted abstracts
The ESMO Symposium on Immuno-Oncology 2015 Scientific Committee will select abstracts for presentation during the Symposium and determine the format of the presentations from the following possibilities:
Poster Discussion – Presentation and analysis by an invited speaker highlighting important findings within a disease type or about a common theme plus interactive audience discussion.
Poster – An important method for communicating details of scientific research, posters will be on display for the duration of the Symposium.
All accepted abstracts will be published in the ESMO Symposium on Immuno-Oncology 2015 Abstract Book.
Daura , Ms. , ESMO
Phone: 011-41-91-973-1900
Fax: 011-41-91-973-1902
Email: daura.mella@esmo.org
Daura , Ms. , ESMO
Phone: 011-41-91-973-1900
Fax: 011-41-91-973-1902
Email: daura.mella@esmo.org